Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

65.48 -0.02 (-0.03%)
Streaming Delayed Price Updated: 1:18 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate in Upcoming Conferences
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Why Apogee Therapeutics Stock Triumphed on Thursday ↗
The company aims to raise gross proceeds of roughly $300 million in a new capital-raising effort. 
Via The Motley Fool
Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today ↗
Via Stocktwits
News headline image
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out ↗
The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent. 
Via Investor's Business Daily
News headline image
Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Gold Falls 1%; ProKidney Shares Spike Higher ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Dips 1%; Mustang Bio Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot ↗
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot. 
Via Investor's Business Daily
News headline image
What's going on in today's pre-market session ↗
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
Top 2 Health Care Stocks That May Plunge This Month ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial ↗
Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B is ongoing. 
Via Benzinga
News headline image
Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Webcast to be held Monday, July 7th at 8:00 a.m. ET 
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Why Is Apogee Therapeutics Stock Trading Higher On Monday? ↗
Apogee's APG808 cut key asthma biomarker FeNO by 53% at 12 weeks with no severe adverse events, showing potential for long-term maintenance dosing. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.